PT  - JOURNAL ARTICLE
AU  - Juang, Duane S.
AU  - Juang, Terry D.
AU  - Dudley, Dawn M.
AU  - Newman, Christina M.
AU  - Friedrich, Thomas C.
AU  - O’Connor, David H.
AU  - Beebe, David J.
TI  - Oil Immersed Lossless Total Analysis System (OIL-TAS): Integrated RNA Extraction and Detection for SARS-CoV-2 Testing
AID  - 10.1101/2020.09.30.20204842
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.30.20204842
4099  - http://medrxiv.org/content/early/2020/10/02/2020.09.30.20204842.short
4100  - http://medrxiv.org/content/early/2020/10/02/2020.09.30.20204842.full
AB  - The coronavirus disease 2019 (COVID-19) pandemic exposed difficulties in scaling current quantitative PCR (qPCR)-based diagnostic methodologies for large-scale infectious disease testing. Bottlenecks include the lengthy multi-step process of nucleic acid extraction followed by qPCR readouts, which require costly instrumentation and infrastructure, as well as reagent and plastic consumable shortages stemming from supply chain constraints. Here we report a novel Oil Immersed Lossless Total Analysis System (OIL-TAS), which integrates RNA extraction and detection onto a single device that is simple, rapid, cost effective, uses minimal supplies and requires reduced infrastructure to perform. We validated the performance of OIL-TAS using contrived samples containing inactivated SARS-CoV-2 viral particles, which show that the assay can reliably detect an input concentration of 10 copies/μL and sporadically detect down to 1 copy/μL. The OIL-TAS method can serve as a faster, cheaper, and easier-to-deploy alternative to current qPCR-based methods for infectious disease testing.Competing Interest StatementThe authors have potential conflicts of interest. David J. Beebe holds equity in Bellbrook Labs LLC, Tasso Inc., Salus Discovery LLC, Lynx Biosciences Inc., Stacks to the Future LLC, Turba LLC, Onexio Biosystems LLC, and Flambeau Diagnostics LLC. David J. Beebe is also a consultant for Abbott Laboratories. Duane S. Juang holds equity in Turba LLC.Funding StatementThis study was funded by a UW WARF COVID-19 Accelerator Challenge award and the National Institutes of Health (NIH 1R01CA247479, NIH P30CA014520, NIH 1R01CA247479-01, NIH OD011106, NIH 5UL1TR002373-03).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable. The study does not involve human subjects.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data generated in this study are available within the article and its supplementary information.